Увійти

Готові списки джерел за темами / Anti-MRSA activity

Добірка наукової літератури з теми "Anti-MRSA activity"

Автор: Grafiati

Опубліковано: 22 червня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Anti-MRSA activity".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

Статті в журналах
Дисертації
Книги
Тези доповідей конференцій

Статті в журналах з теми "Anti-MRSA activity":

1

Asnani, Ari, Eva Luviriani, and Oedjijono Oedjijono. "Activity of Actinomycetes Isolated from Mangrove Segara Anakan Cilacap toward Methicillin-resistant Staphylococcus aureus (MRSA)." Jurnal Kimia Sains dan Aplikasi 23, no. 1 (December 6, 2019): 1–7. http://dx.doi.org/10.14710/jksa.23.1.1-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Methicillin-resistant Staphylococcus aureus (MRSA) is a major health concern because it causes numerous infections in both healthcare facilities and communities. The development of multiresistant against topical antibiotics has caused substantial difficulty in the management of Staphylococcus infection. Thus, this research was aimed to explore indigenous marine Actinomycetes isolated from Segara Anakan Cilacap for anti-MRSA activity. The methods used were screening anti-MRSA activity using agar-block method, production of anti-MRSA extract, extraction of the anti-MRSA extract with ethyl acetate, MIC determination of the ethyl-acetate extract, and species identification based on morphology and 16S rRNA genes. The results indicated that 14 out of 16 Actinomycetes have anti-MRSA activity. Three isolates, which were W-5B, W-5A, and P-7D, showed the highest anti-MRSA activity with the inhibition zone of 2.40 mm, 1.20 mm, and 0.80 mm, respectively. The minimum inhibitory concentration (MIC) of ethyl acetate extract from isolates W-5B, W-5A, and P-7D against MRSA were 2 mg/mL, 4 mg/mL, and 8 mg/mL, respectively. The species identification based on 16S rRNA genes indicated that Actinomycetes W-5B isolate has 92.51% similarity with Streptomyces sp. 2011. The W-5A has 94.69% similarity with Arthrobacter sp. HZ11. The P-7D has 94.79% similarity with Streptomyces clavuligerus strain A-ZN-05. The present study concludes that marine Actinomycetes from sediment mangrove in Segara Anakan Cilacap, Indonesia, has potency as anti-MRSA.

2

Kubo, Isao, Ping Xiao, and Ken'ichi Fujita. "Anti-MRSA activity of alkyl gallates." Bioorganic & Medicinal Chemistry Letters 12, no. 2 (January 2002): 113–16. http://dx.doi.org/10.1016/s0960-894x(01)00663-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Yao, Cheng-Jiao, Yi-lin Li, Meng-Jun Pu, Li-Hong Luo, Qin Xiong, Feng-Jiao Xie, Ting-Lin Li, and Pei-Min Feng. "Aminoglycosides with Anti-MRSA Activity: A Concise Review." Current Topics in Medicinal Chemistry 21, no. 27 (December 8, 2021): 2483–99. http://dx.doi.org/10.2174/1568026621666211004093647.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Methicillin-resistant Staphylococcus aureus (MRSA), a leading cause of infections in human being and is usually associated with a multidrug-resistant profile, represents a significant health threat and public burden globally. The limited options of effective antibiotics motivate the search for novel anti-MRSA agents. Aminoglycoside antibiotics have been extensively applied in the medical field due to their desirable broad-spectrum antibacterial activity, especially for systemic infections caused by Gram-negative organisms. Recent studies demonstrated that aminoglycosides also possessed potential activity against MRSA, so aminoglycosides may be useful weapons to fight against MRSA. The present work aims to summarize the current scenario of aminoglycosides with anti- MRSA potential, covering articles published between 2010 and 2020. The structure-activity relationship and the mechanism of action are also discussed for the further rational design of novel potential drug candidates.

4

Yao, Cheng-Jiao, Yi-lin Li, Meng-Jun Pu, Li-Hong Luo, Qin Xiong, Feng-Jiao Xie, Ting-Lin Li, and Pei-Min Feng. "Aminoglycosides with Anti-MRSA Activity: A Concise Review." Current Topics in Medicinal Chemistry 21, no. 27 (December 8, 2021): 2483–99. http://dx.doi.org/10.2174/1568026621666211004093647.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Methicillin-resistant Staphylococcus aureus (MRSA), a leading cause of infections in human being and is usually associated with a multidrug-resistant profile, represents a significant health threat and public burden globally. The limited options of effective antibiotics motivate the search for novel anti-MRSA agents. Aminoglycoside antibiotics have been extensively applied in the medical field due to their desirable broad-spectrum antibacterial activity, especially for systemic infections caused by Gram-negative organisms. Recent studies demonstrated that aminoglycosides also possessed potential activity against MRSA, so aminoglycosides may be useful weapons to fight against MRSA. The present work aims to summarize the current scenario of aminoglycosides with anti- MRSA potential, covering articles published between 2010 and 2020. The structure-activity relationship and the mechanism of action are also discussed for the further rational design of novel potential drug candidates.

5

Imamura, Hideaki, Norikazu Ohtake, Hideki Jona, Aya Shimizu, Minoru Moriya, Hiroki Sato, Yuichi Sugimoto, et al. "Dicationic dithiocarbamate carbapenems with anti-MRSA activity." Bioorganic & Medicinal Chemistry 9, no. 6 (June 2001): 1571–78. http://dx.doi.org/10.1016/s0968-0896(01)00044-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Ohtake, Norikazu, Hideaki Imamura, Hideki Jona, Hideo Kiyonaga, Aya Shimizu, Minoru Moriya, Hiroki Sato, Masato Nakano, Ryosuke Ushijima, and Susumu Nakagawa. "Novel dithiocarbamate carbapenems with anti-MRSA activity." Bioorganic & Medicinal Chemistry 6, no. 7 (July 1998): 1089–101. http://dx.doi.org/10.1016/s0968-0896(98)00069-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Ohtake, Norikazu, Hideaki Imamura, Hideo Kiyonaga, Hideki Jona, Masayuki Ogawa, Shigemitsu Okada, Aya Shimizu, et al. "Novel dithiocarbamate carbapenems1 with anti-MRSA activity." Bioorganic & Medicinal Chemistry Letters 7, no. 13 (July 1997): 1617–22. http://dx.doi.org/10.1016/s0960-894x(97)00272-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Yee, Cheung, Donald Biek, Kevin Krause, and Gregory Williams. "Ceftaroline: a Cephalosporin with Anti-MRSA Activity." Clinical Microbiology Newsletter 33, no. 21 (November 2011): 161–69. http://dx.doi.org/10.1016/j.clinmicnews.2011.10.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Cao, Feng, Wei Peng, Xiaoli Li, Ming Liu, Bin Li, Rongxin Qin, Weiwei Jiang, et al. "Emodin is identified as the active component of ether extracts from Rhizoma Polygoni Cuspidati, for anti-MRSA activity." Canadian Journal of Physiology and Pharmacology 93, no. 6 (June 2015): 485–93. http://dx.doi.org/10.1139/cjpp-2014-0465.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

This study investigated the anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) activity and chemical compositions of ether extracts from Rhizoma Polygoni Cuspidati (ET-RPC). Significant anti-MRSA activities of ET-RPC against MRSA252 and MRSA clinical strains were tested in in vitro antibacterial experiments, such as inhibition zone diameter test, minimal inhibitory concentration test, and dynamic bacterial growth assay. Subsequently, 7 major compounds of ET-RPC were purified and identified as polydatin, resveratrol-4-O-d-(6′-galloyl)-glucopyranoside, resveratrol, torachryson-8-O-glucoside, emodin-8-O-glucoside, 6-hydroxy-emodin, and emodin using liquid chromatography – electrospray ionization – tandem mass spectrometry. After investigation of anti-MRSA activities of the 7 major compounds, only emodin had significant anti-MRSA activity. Further, transmission electron microscopy was used to observe morphological changes in the cell wall of MRSA252, and the result revealed that emodin could damage the integrity of cell wall, leading to loss of intracellular components. In summary, our results showed ET-RPC could significantly inhibit bacterial growth of MRSA strains. Emodin was identified as the major compound with anti-MRSA activity; this activity was related to destruction of the integrity of the cell wall and cell membrane.

10

Yu, Moxi, Yachen Hou, Meiling Cheng, Yongshen Liu, Caise Ling, Dongshen Zhai, Hui Zhao, et al. "Antibacterial Activity of Squaric Amide Derivative SA2 against Methicillin-Resistant Staphylococcus aureus." Antibiotics 11, no. 11 (October 28, 2022): 1497. http://dx.doi.org/10.3390/antibiotics11111497.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Methicillin-resistant Staphylococcus aureus (MRSA)-caused infection is difficult to treat because of its resistance to commonly used antibiotic, and poses a significant threat to public health. To develop new anti-bacterial agents to combat MRSA-induced infections, we synthesized novel squaric amide derivatives and evaluated their anti-bacterial activity by determining the minimum inhibitory concentration (MIC). Additionally, inhibitory activity of squaric amide 2 (SA2) was measured using the growth curve assay, time-kill assay, and an MRSA-induced skin infection animal model. A scanning electron microscope and transmission electron microscope were utilized to observe the effect of SA2 on the morphologies of MRSA. Transcriptome analysis and real-time PCR were used to test the possible anti-bacterial mechanism of SA2. The results showed that SA2 exerted bactericidal activity against a number of MRSA strains with an MIC at 4–8 µg/mL. It also inhibited the bacterial growth curve of MRSA strains in a dose-dependent manner, and reduced the colony formation unit in 4× MIC within 4–8 h. The infective lesion size and the bacterial number in the MRSA-induced infection tissue of mice were reduced significantly within 7 days after SA2 treatment. Moreover, SA2 disrupted the bacterial membrane and alanine dehydrogenase-dependent NAD+/NADH homeostasis. Our data indicates that SA2 is a possible lead compound for the development of new anti-bacterial agents against MRSA infection.

Більше джерел

Дисертації з теми "Anti-MRSA activity":

1

Lima, Bruna de Araujo 1985. "Análise dos mecanismos da atividade antimicrobiana da violaceína sobre Staphylococcus aureus = Analysis of antimicrobial activity mechanisms of violacein against Staphylococcus aureus." [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/317022.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Orientador: Marcelo Brocchi
Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia
Made available in DSpace on 2018-08-23T15:34:06Z (GMT). No. of bitstreams: 1 Lima_BrunadeAraujo_D.pdf: 3794605 bytes, checksum: 178a4bf447e5292f789a4713d5500b38 (MD5) Previous issue date: 2013
Resumo: A violaceína é um pigmento violeta produzido por algumas espécies bacterianas de origem ambiental, tais como Chromobacterium violaceum e Janthinobacterium lividum. Esta molécula apresenta várias propriedades biológicas incluindo antibacteriana, antifúngica, antiviral, antiprotozoária e antitumoral, apesar de sua função exata na fisiologia dos micro-organismos que a produz, ainda é desconhecido. No presente trabalho, a atividade antimicrobiana da violaceína produzida comercialmente, o extrato semi purificado e nanopartículas de vanadato de prata foram avaliados contra espécies de bacterianas gram-positivas e gram-negativas. A violaceína exibiu efeito antimicrobiano contra Staphylococcus aureus resistente à meticilina (MRSA) e Enterococcus resistente à vancomicina (VRE), que são micro-organismos frequentemente relacionados com infecções adquiridas em hospitais. Os valores de MIC (concentração inibitória mínima) e MBC (concentração bactericida mínima) da violaceína produzida comercialmente foram de 0,625 ?M e 1,25 ?M respectivamente e, análise de curvas de crescimento e tempo-morte revelaram um efeito antibacteriano durante 12 horas contra MRSA. A microscopia eletrônica de transmissão mostrou os efeitos da violaceína com alterações morfológicas e ultra estruturais, incluindo alterações na parede celular e formação de septos de divisão anormais. Nos resultados obtidos das análises de proteômica e transcriptoma a violaceína afetou a expressão de várias classes funcionais de proteínas e genes em MRSA, incluindo processos biológicos em biossíntese da parede celular e divisão celular que corroboram as alterações ultra estruturais visualizadas. Em conclusão, a violaceína produzida comercialmente demonstrou atividade antimicrobiana para S. aureus MRSA e pela primeira vez, os efeitos da violaceína sobre o metabolismo de S. aureus foram descritos, indicando possíveis alvos e vias metabólicas afetadas por esta droga. No seu conjunto, estes dados indicam a violaceína como uma droga potencial para o tratamento de infecções provocadas por MRSA
Abstract: Violacein is a violet pigment produced by some bacterial species of environmental source, such as Chromobacterium violaceum and Janthinobacterium lividum. This molecule has numerous biological properties including antibacterial, antifungal, antiviral, antiprotozoal and antitumor activity, although the exact role in the physiology of producing microorganisms is still unknown. In this study, the antimicrobial activity of violacein produced commercially, semi purified extract and silver vanadate nanoparticles were evaluated against several species of gram-positive and gram-negative bacteria. Violacein exhibited antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), microorganisms that are often related to hospital-acquired infections. MIC (minimum inhibitory concentration) and MBC (minimum bactericidal concentration) values of violacein produced commercially were 1.25 ?M mM and 0.625 ?M respectively, and analysis of growth and time-kill curves showed an antibacterial effect against MRSA for 12 hours. The transmission electron microscopy showed the effects of violacein with morphological and ultra-structural changes, including changes in cell wall formation and abnormal division septum. The results obtained from the analysis of proteomic and transcriptomic revealed that violacein affects the expression of several functional classes of proteins and genes in MRSA, including biological processes in cell wall biosynthesis and cell division, supporting ultra-structural changes. In conclusion, violacein produced commercially demonstrated antimicrobial activity against S. aureus MRSA and the effects on the metabolism of S. aureus have been described, indicating possible targets and pathways affected by this drug. These data indicate violacein as a potential drug for the treatment of infections caused by MRSA
Doutorado
Microbiologia
Doutora em Genética e Biologia Molecular

2

Bhattacharya, Biplob. "Synthesis and Anti-MRSA Activity of Hydrophilic C3-Acylated N-Thiolated β-Lactams and N-Acyl Ciprofloxacin-N-Thiolated β-Lactam Hybrids". Scholar Commons, 2012. http://scholarcommons.usf.edu/etd/4289.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The Turos laboratory has been working with N-thiolated β-lactams for years trying to understand the mode of action and structural features it needs to have biological activity. Over the years new data has shown promising inhibitory activity against various microbes. In this dissertation, a review of the vast amount of work carried out on N-thiolated β-lactams in Turos laboratory has been done and their novelty, in terms of structure and mechanism has been discussed. A complete outline of our work in the discovery and ongoing development of these compounds, starting from our initial, unexpected finding of antimicrobial activity for one of the lead compounds, to a more complete understanding of their chemical and biological mode of action and potential utility as antibacterial compounds, has been provided. Previous researches by graduate students in the Turos laboratory have shown that N-thiolated β-lactams targets Type II Fatty Acid Synthesis (FAS). In process of understanding this further, other FAS inhibiting antibiotics like Triclosan were compared to our lactams by adding excess of exogenous fatty acids. Results revealed vast differences in the MIC value of triclosan and N-thiolated β-lactams, giving an idea that there might be a different mode of action or a different target altogether. The third chapter discusses the study of attaching hydrophilic C3 side chains like amino acids and carbohydrates on N-thiolated β-lactams while studying the influence of microbiological activity. From the study it was found that the lengthening of the side chain halts the inhibitory activity regardless of whether the side chain contains unsaturation or branching. Results showed that polar groups were not well tolerated and the inhibitory activity goes down regardless of polarity. Finally, research on dual-action antibiotics was discussed. Antibiotics cause continuous bacterial resistance and in this aspect use of two drugs with different mode of action can call for reduction of the resistance. Herein, N-acyl ciprofloxacin and N-thiolated β-lactams were connected together via an ester linkage. Six new hybrid compounds have been synthesized successfully and tested against E. faecium, K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae.

3

Hakem, Asma. "Les métabolites spécialisés du genre Juncus : approfondissement de leur potentiel antimicrobien et étude de leur biodisponibilité." Electronic Thesis or Diss., Université de Lille (2022-....), 2023. https://pepite-depot.univ-lille.fr/ToutIDP/EDSMRE/2023/2023ULILR040.pdf.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

La recherche de nouveaux antimicrobiens est actuellement cruciale pour faire face aux maladies émergentes (pandémie de la COVID-19) et à la résistance aux antibiotiques. La présente étude vise à mettre en exergue le potentiel d'espèces végétales, sélectionnées sur la base de critères écologiques et chimiotaxonomiques, comme source naturelle de composés dotés d'une grande diversité structurale et d'un éventail d'activités biologiques prometteuses. Des espèces de Juncus, collectées à partir de 3 localités en France, ont été étudiées pour leur potentiel antiviral contre les coronavirus et antibactérien contre des souches bactériennes à Gram positif. À cet effet, l'approche du fractionnement bioguidé employant des techniques séparatives conventionnelles (HPLC préparative et CPC), a été adoptée. L'étude de l'activité antivirale menée contre le coronavirus HCoV-229E a mis en évidence le pouvoir antiviral de la lutéoline isolé à partir du sous extrait AcOEt des tiges de J. acutus (localité 2). Le criblage de l'activité antibactérienne a souligné un effet remarquable du sous-extrait CH2Cl2 des rhizomes de J. inflexus (localité 3), enrichi en composés phénanthréniques, notamment contre les souches de S. aureus. Ainsi, des expériences complémentaires, permettant d'approfondir la compréhension de l'effet antibactérien de certains des composés phénanthréniques isolés, ont été réalisées en orientant le travail sur une souche de S. aureus résistante à la méticilline (SARM) et provenant d'un prélèvement sur un pied diabétique. Suite aux résultats promoteurs obtenus, le développement d'une formulation topique à base de juncusol a été initié. Des travaux portant sur la biodisponibilité de ce composé phénanthrénique ont été également réalisés par le biais d'expériences de passage de barrière intestinale in vitro au moyen de cocultures cellulaires Caco-2/HT29-MTX
To address the current challenges raised by emerging diseases (COVID-19 pandemic) and antibiotic resistance, the search for new antimicrobials has become urgent. The present study aims to highlight the potential of plant species, selected according to ecological and chemotaxonomic criteria, as a natural source of compounds with a wide structural diversity and promising biological activities. Juncus species collected from 3 localities in France were investigated for their potential antimicrobial effect against coronaviruses and Gram-positive bacterial strains. For this purpose, the approach of bioguided fractionation was adopted through the use of conventional separation techniques (preparative HPLC and CPC). The antiviral study conducted against the coronavirus HCoV-229E highlighted the antiviral potential of luteolin, a flavone that was isolated from the EtOAc sub-extract of J. acutus stems (locality 2). The screening for antibacterial activity led to the selection of the CH2Cl2 sub-extract of J. inflexus rhizomes (locality 3) for the rest of this study as this enriched-phenanthrene derivative sub-extract demonstrated a remarkable activity in particular against S. aureus strains. Additional experiments to deepen the understanding of the antibacterial effect of some of the isolated phenanthrene derivatives were performed focusing on a methicillin-resistant S. aureus strain that was isolated from a diabetic foot infection. Regarding the promising results, the developement of a topical formulation involving juncusol as an active component was initiated. Bioavailibility studies were also performed on this phenanthrene derivative through in vitro absorption and intestinal permeability experiments across Caco2/HT29-MTX co-cultured cells

Книги з теми "Anti-MRSA activity":

1

Emami, Saeed. New quinolones with potential anti-MRSA activity. Hauppauge, N.Y: Nova Science, 2009.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Anti-MRSA activity":

1

Aunpad, Ratchaneewan, Siriporn Kaewklom, and Watanalai Panbangred. "Two Putative Holin-Like Peptide with Anti-MRSA Activity and Their Potential Application." In The Twenty-Third American and the Sixth International Peptide Symposium. Prompt Scientific Publishing, 2013. http://dx.doi.org/10.17952/23aps.2013.032.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Teixeira, Julia, Felipe Saraiva, Vinícius Gonçalves, Renata Bastos, Laianne Inácio, Juliana Boechat, Juliana Silva, Ana Argondizzo, Haroldo Júnior, and José Senna. "Assessment of the activity of the anti-PBP2a monoclonal antibody from methicillin-resistant Staphylococcus aureus (MRSA) against Enterococcus spp." In International Symposium on Immunobiological. Instituto de Tecnologia em Imunobiológicos, 2024. http://dx.doi.org/10.35259/isi.biomang.2024_63894.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.